STLN
Starling Oncology, Inc.NasdaqResearch view
$6.66+2.30%
Sep 25 close · 1D EOD · Databento
HealthcareServices-Offices & Clinics Of Doctors Of MedicineSmall-capSEC EDGAR FY 2025-12-31
The numbers · FY2025, filed
SEC EDGARMarket cap$679M
Revenue$502.7M+27.80%
Net income$60.6B
EPS, diluted$-0.54+23.90%
Operating margin-7.2%
Return on equity-385534.4%
All filed figures
Snapshot
SEC EDGAR · FY 2025-12-31SectorHealthcare
Market Cap$678.8M
Enterprise Value$722.6M
Income$60.6B
Sales$502.7M
Book/sh$-0.15
Cash/sh$0.33
Dividend TTM—
Payout—
Employees—
IPO—
Quick Ratio1.35
Current Ratio1.59
Debt/Eq-4.92
EPS (ttm)$-0.54
EPS this Y23.9%
EPS past 3/5Y—
Sales past 3/5Y25.8%
EPS Y/Y TTM23.9%
Sales Y/Y TTM27.8%
Shs Outstand101.92M
ROA36807.6%
ROE-385534.4%
ROIC-128.1%
Gross Margin—
Oper. Margin-7.2%
Profit Margin12055.4%
Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.
Revenue by fiscal year
$203.0M
FY21
$252.5M
FY22
$324.2M
FY23
$393.4M
FY24
$502.7M
FY25
Operating leverage — margins
GrossOperatingNet
Financials, annual · income and cash flowSEC EDGAR · open ▸
Financials — annual
SEC EDGAR · last 5 FY · tap a row to explain it| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $203.0M | $252.5M | $324.2M | $393.4M | $502.7M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-45.9M | $-82.0M | $-77.0M | $-60.1M | $-36.1M |
| Net Income | $-10.9M | $152,000 | $-83.1M | $64.7B | $60.6B |
| Diluted EPS | $-0.16 | $-0.21 | $-0.92 | $-0.71 | $-0.54 |
| Operating Cash Flow | $-32.7M | $-61.8M | $-36.3M | $-26.5M | $-24.6M |
| Free Cash Flow | $-35.5M | $-67.3M | $-40.9M | $-30.3M | $-27.8M |
Same industry
In the screener →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.